R1	Has_qualifier Arg1:T1 Arg2:T3	
R2	AND Arg1:T1 Arg2:T2	
R3	Has_negation Arg1:T5 Arg2:T4	
R4	Has_value Arg1:T6 Arg2:T7	
R5	AND Arg1:T5 Arg2:T6	
R6	Has_index Arg1:T8 Arg2:T9	
R7	Has_temporal Arg1:T5 Arg2:T8	
R8	Has_index Arg1:T12 Arg2:T13	
R9	Has_temporal Arg1:T11 Arg2:T12	
*	OR T14 T16
R10	Has_value Arg1:T14 Arg2:T15	
R11	Has_value Arg1:T16 Arg2:T17	
R12	Has_value Arg1:T18 Arg2:T19	
R13	Has_value Arg1:T20 Arg2:T21	
R14	Has_value Arg1:T22 Arg2:T23	
R15	Has_index Arg1:T29 Arg2:T30	
R16	Has_temporal Arg1:T28 Arg2:T29	
R17	Has_value Arg1:T24 Arg2:T25	
R18	Has_value Arg1:T26 Arg2:T27	
*	OR T24 T26
R19	Subsumes Arg1:T22 Arg2:T24	
R20	Has_value Arg1:T34 Arg2:T35	
T1	Procedure 11 27	cardiac ablation
T2	Condition 32 34	AF
T3	Qualifier 0 10	Successful
T4	Negation 47 54	freedom
T5	Condition 60 73	AF recurrence
T6	Condition 103 125	arrhythmic recurrences
T7	Value 134 156	longer than 30 seconds
T8	Temporal 158 200	3 months after successful cardiac ablation
T9	Reference_point 184 200	cardiac ablation
T10	Non-query-able 202 258	AF recurrence during 3-month blanking period is excluded
T11	Drug 312 335	anticoagulation therapy
T12	Temporal 340 386	at least two (2) months prior to randomization
T13	Reference_point 373 386	randomization
T14	Measurement 406 418	CHADS2 score
T15	Value 419 422	= 2
T16	Measurement 426 444	CHA2DS2-VASc score
T17	Value 446 448	=3
T18	Measurement 451 485	Left ventricular ejection fraction
T19	Value 486 491	> 25%
T20	Measurement 493 500	LA size
T21	Value 501 505	< 65
T22	Observation 512 542	risk for thromboembolic events
T23	Value 507 511	High
T24	Measurement 550 562	CHADS2 score
T25	Value 563 566	= 2
T26	Measurement 570 588	CHA2DS2-VASc score
T27	Value 589 592	= 3
T28	Drug 606 609	OAT
T29	Temporal 610 644	before undergoing cardiac ablation
T30	Reference_point 628 644	cardiac ablation
T32	Post-eligibility 647 725	ble and willing to comply with all pre- and follow-up testing and requirements
T33	Informed_consent 727 755	Signed informed consent form
T34	Person 757 760	Age
T35	Value 761 778	18 years or older
